Inogen Inc

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Inogen Has Reported 121.6% Growth YTD

    Inogen (INGN) reported a rise in its stock of 121.6%, from $119.17 on January 2, 2018, to $263.85 on September 7, 2018.

    By Margaret Patrick
  • uploads///puzzle _
    Company & Industry Overviews

    Crispr Therapeutics Stock Fell 12.6% on June 11

    On June 11, Crispr Therapeutics (CRSP) stock fell 12.6% to $59.57 over concerns that the CRISPR-CAS9 Gene Therapy causes cancer.

    By Mike Benson
  • uploads///GMED SGA
    Company & Industry Overviews

    A Deep Look at Globus Medical’s Financial Performance

    In 3Q17, Globus Medical (GMED) generated sales of $151.7 million compared to $135.6 million in 3Q16.

    By Kenneth Smith
  • uploads///GMED REvenue
    Company & Industry Overviews

    Taking Stock of Globus Medical’s Recent Acquisitions

    Most of Globus Medical’s revenue comes from the United States, and the rest comes from its international segment. In 3Q17, the United States contributed $125.9 million.

    By Kenneth Smith
  • uploads///GMED analysts reco
    Company & Industry Overviews

    Analyst Ratings for Globus Medical and Its Peers in February

    Of the 13 analysts covering Globus Medical in February 2018, seven of them have given the stock a “buy” or higher rating. Five analysts have given it a “hold.”

    By Kenneth Smith
  • uploads///MDXG EPS Trend
    Company & Industry Overviews

    Behind MiMedx Group’s Recent Financial Performance

    In 3Q17, MiMedx Group’s (MDXG) net sales rose to $84.6 million, compared with $64.4 million in 3Q16—a 31% YoY (year-over-year) rise.

    By Kenneth Smith
  • uploads///pain injection market
    Company & Industry Overviews

    Why the Physician Office Pain Management Market Matters to MiMedx

    Through MiMedx’s donor program, a mother scheduled to deliver a baby by C-section can donate her placental tissue rather than leave it as medical waste.

    By Kenneth Smith
  • uploads///MDXG RD Trend
    Company & Industry Overviews

    Which Markets Is MiMedx Group Actually Targeting?

    MiMedx estimates that the domestic skin and dermal substitute market will reach sales of $1.1 billion in 2020.

    By Kenneth Smith
  • uploads///MDXG _revenue growth
    Company & Industry Overviews

    Understanding MiMedx Group’s Zealous Focus on Sales

    MiMedx focuses on marketing efforts to increase revenues. The company has at its disposal a sales force of 320 professionals.

    By Kenneth Smith
  • uploads///MDXGanalysts Reco
    Company & Industry Overviews

    MiMedx Group on the Street: Analyst Recommendations in January

    Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.

    By Kenneth Smith
  • uploads///Antares Pharmas pipeline
    Company & Industry Overviews

    Antares Pharma’s Sale of ZomaJet to Ferring Pharmaceuticals

    ZomaJet is Antares Pharma’s needle-free autoinjector, which is designed to deliver human growth hormone (or HGH) treatment to children with growth retardation.

    By Kenneth Smith
  • uploads///Antares Analyst Estimates
    Company & Industry Overviews

    Analysts’ Recommendations for Antares Pharma in November 2017

    Antares Pharma’s (ATRS) products include Vibex, a pressure-assisted autoinjector. The global injectable drug delivery market is expected to grow to $624.5 billion by 2021.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.